A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer
Brief description of study
Magrolimab is a novel immune checkpoint inhibitor (targeting macrophages in the tumor to support killing of tumor). The purpose of the study is to determine and evaluate magrolimab in combination with either nab-paclitaxel or paclitaxel for patients with untreated Metastatic Triple-Negative Breast Cancer. This study consists of two parts: the first part will include the Safety Run-in Cohort. The aim is to assess magrolimab in combination with choice of nab-paclitaxel or paclitaxel in patients previously untreated for unresectable, locally advanced or metastatic Triple Negative Breast Cancer whose tumors are not appropriate for immune checkpoint inhibitor therapy. The second part of the study is to assess magrolimab in combination with choice of nab-paclitaxel or paclitaxel versus nab-paclitaxel or paclitaxel in patients previously untreated fmetastatic Triple Negative Breast Cancer whose tumors are not appropriate for immune checkpoint inhibitor therapy (are PD-L1 negative).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
